Scalable Bayesian structure learning of directed acyclic graphs via Laplace approximation, with an application to breast cancer gene expression networks
A Laplace-approximated Bayesian scoring function for the non-conjugate Normal--Gamma prior is developed and, through the DAG-probit extension, predicts malignancy from nuclear morphometry with a cross-validated ROC-AUC of $0.94$ using a sparse, interpretable set of direct predictors.
Abstract
Structure learning of directed acyclic graphs (DAGs) from observational data is a foundational task in causal discovery and is widely used to infer regulatory networks from medical and genomic measurements. The Bayesian formulation quantifies model uncertainty and admits prior biological knowledge, but its practical use has been hampered by the super-exponential growth of the DAG space and by the intractability of the node-marginal likelihood under flexible, non-conjugate priors. Existing closed-form solutions are largely confined to the conjugate Normal--Inverse-Gamma prior. We develop a Laplace-approximated Bayesian scoring function for the non-conjugate Normal--Gamma prior on the modified Cholesky parameterisation of the precision matrix, embed it in a Metropolis--Hastings sampler over DAGs, and couple the latent Gaussian network to a binary clinical outcome through a probit link. We show that the node-marginal integral is of generalised inverse-Gaussian form, so that its exact value is a modified Bessel function of the second kind and the proposed scoring function is its leading large-argument asymptotic; the posterior of each conditional variance is likewise generalised inverse-Gaussian and is sampled exactly. In simulation, the proposed prior improves on the conjugate baseline and on the PC, greedy-equivalence-search, NOTEARS, and DAGMA benchmarks at sample sizes typical of clinical cohorts. On two real datasets, the Sachs protein-signalling network, scored against its validated consensus graph, and the Wisconsin Diagnostic Breast Cancer data, the method recovers known structure and, through the DAG-probit extension, predicts malignancy from nuclear morphometry with a cross-validated ROC-AUC of $0.94$ using a sparse, interpretable set of direct predictors.
Results show the framework identifies sparse, interpretable, externally supported drug-sensitivity markers while enabling principled investigation of tissue-specific departures from shared effects, as well as improving sensitivity recovery under network-structured signal.
Hammed A. Olayinka, Saheed O. Olayemi· 0 citations
SVI-DAG is proposed, a structured variational inference approach to Bayesian causal discovery using observational data and prior beliefs that uses normalizing flows to model dependencies between edges, supporting expressive and multimodal posterior learning over DAGs.
This work proposes SURE-Ridge, a non-iterative, closed-form estimator for equal variance linear Gaussian SEM, which achieves the lowest structural Hamming distance in the small-sample regime and the lowest run time across all sample sizes tested, compared with NOTEARS, DAGMA, and GBNSL baselines.
This work introduces BERGM Elastic Net, an adaptive empirical-Bayes approach that combines lasso shrinkage with ridge stabilization in a Bayesian ERGM that is developed for over-specified network models containing many related structural and covariate effects.
Dan Han, Vicki Modisette, Tinghan Li et al.· 0 citations
The results show that representing both sources as probabilistic uncertainty over edge existence and orientation is a practical and effective way to improve causal graph accuracy.
N. K. Kitson, Anthony C. Constantinou· 0 citations
This article proposes an innovative framework, INLA-MBN, that integrates multilevel BNs (MBNs) with the integrated nested Laplace approximation (INLA), thereby facilitating efficient structure and parameter learning in both longitudinal and cross-sectional multilevel data contexts.
B. E. Yirdaw, L. K. Debusho, J. van Niekerk et al.· Statistical Methods in Medic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.